iwCLL 2019 | Entospletinib in combination with obinutuzumab in R/R CLL

Adam Kittai

Adam Kittai, MD, Ohio State University, Columbus, OH, gave an overview of the phase I/II study of entospletinib in combination with obinutuzumab in patients with R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video